Electronic Acknowledgement Receipt					
EFS ID:	1118372				
Application Number:	10807837				
Confirmation Number:	4419				
Title of Invention:	Anti-IL-22RA antibodies and binding partners and methods of using in inflammation				
First Named Inventor:	Wenfeng Xu				
Correspondence Address:	Jennifer K. Johnson ZymoGenetics, Inc. 1201 Eastlake Avenue East - Seattle WA 98102 US 2064426676 -				
Filer:	Shelby J. Walker./Linda Povinelli				
Filer Authorized By:	Shelby J. Walker.				
Attorney Docket Number:	03-02				
Receipt Date:	18-JUL-2006				
Filing Date:	24-MAR-2004				
Time Stamp:	21:05:43				
Application Type:	Utility				
International Application Number:					
Payment information:					

Payment information:

Submitted with Payment	no	
------------------------	----	--

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1	Response to Election / Restriction Filed	03-02ResponseToRestriction .pdf	46152	no	2
Warnings:					
Information:					
	Total Files Size (in bytes): 46152				

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.